Comparative Pharmacology
Head-to-head clinical analysis: BEPOTASTINE BESILATE versus LASTACAFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEPOTASTINE BESILATE versus LASTACAFT.
BEPOTASTINE BESILATE vs LASTACAFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
2 mg/mL ophthalmic solution: 1 drop in each affected eye twice daily.
1 drop in each affected eye twice daily (approximately every 8 hours)
None Documented
None Documented
Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis.
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%).
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine